WeChat· 多肽圈·· 10 hours agoPickScore69
Merck KGaA to Acquire Silence Therapeutics for About $1.3 Billion in Cash
In brief
Merck KGaA has announced a cash acquisition of UK clinical-stage siRNA company Silence Therapeutics for approximately $1.3 billion in equity value, with an enterprise value of $1.1 billion. The company's core asset is a potentially best-in-class siRNA therapy approaching Phase 3 for polycythemia vera. The cash price is $20 per ADS, with each ADS representing three ordinary shares, equivalent to $6.6667 per ordinary share.
Why it matters
The roughly $1.3 billion cash deal gives Merck KGaA a Phase 3-bound siRNA therapy for PV, letting readers assess siRNA platform deal valuation in that indication.
Source: WeChat · mp.weixin.qq.com